Is Kwality Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Is Kwality Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 3,394 as of 15 October 2026, within its 52-week range of Rs 1,561.00 to Rs 3,949.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Kwality Pharmaceuticals

Kwality Pharmaceuticals Ltd is a pharmaceutical formulations company based in Amritsar, Punjab. It makes tablets, capsules, injections and other dosage forms, with exports to markets in Africa, Latin America and Asia. At a market capitalisation of Rs 3,520 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.

Is Kwality Pharmaceuticals the Best Stock in Its Sector?

Kwality Pharmaceuticals' case in the sector rests on return quality rather than cheap valuation, since the stock trades at a premium to its Industry P/E. Kwality Pharmaceuticals' 43.43x P/E is above the 36.77x Industry P/E, Ajanta Pharma at 36.31x and Marksans Pharma at 27.32x, while its 20.31% ROE is lower than Ajanta Pharma at 23.33%, though higher than Marksans Pharma at 13.82%, and its debt to equity ratio of 0.39 is above Ajanta Pharma at 0.06 and Marksans Pharma at 0.11.

Metric	Kwality Pharmaceuticals
CMP (NSE)	Rs 3,394.10
52-Week High / Low	Rs 3,949.00 / Rs 1,561.00
Market Cap	Rs 3,520 Cr
P/E (TTM) vs Industry P/E	43.43x vs 36.77x
P/B	10.64
ROE	20.31%
EPS (TTM)	Rs 78.11
Dividend Yield	0.00%
Debt to Equity	0.39

Compare Kwality Pharmaceuticals Against Other Pharmaceuticals Sector Stocks

How Kwality Pharmaceuticals Compares Against Its Pharmaceuticals Sector Peers

The table below sets Kwality Pharmaceuticals against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Kwality Pharmaceuticals	3,520	43.43	20.31%	0.39
Ajanta Pharma	41,211	36.31	23.33%	0.06
Marksans Pharma	14,236	27.32	13.82%	0.11
Peer average (2 companies)	-	31.82	18.57%	0.08

Measured against the peer averages, Kwality Pharmaceuticals' P/E is 37 percent above the 31.82x average, and its ROE is 1.73 percentage points above the 18.57% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Kwality Pharmaceuticals Worth Watching in Pharmaceuticals

• Scale: At Rs 3,520 Cr, its market capitalisation is smaller than Ajanta Pharma (Rs 41,211 Cr) and Marksans Pharma (Rs 14,236 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Export orders from emerging markets and new product registrations are the main growth levers.
• Key risk: With a market capitalisation near Rs 3,500 Cr, it is small, and the stock has risen sharply from its yearly low, so volatility and liquidity are real considerations.

Kwality Pharmaceuticals Valuation: Is It Justified?

At a P/B ratio of 10.64, the market pays about Rs 10.64 for every rupee of book value, and the EPS (TTM) of Rs 78.11 is the earnings base behind the P/E. The stock trades about 14 percent below its 52-week high and about 2.2 times its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Kwality Pharmaceuticals and other Pharmaceuticals sector stocks.

How to Track Kwality Pharmaceuticals Before You Invest

Before deciding whether Kwality Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.

1. Open the Univest Screener and search for Kwality Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.
2. Compare its P/E, P/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Kwality Pharmaceuticals gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades above its sector benchmark, execution matters more than usual if the current valuation is to hold. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Kwality Pharmaceuticals the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Kwality Pharmaceuticals has a 20.31% ROE and trades at 43.43x P/E against a 36.77x Industry P/E. Against the 2 peers compared in this article, its ROE is above the 18.57% peer average and its P/E is above the 31.82x peer average. Its debt to equity ratio of 0.39 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Kwality Pharmaceuticals?

Ans. Kwality Pharmaceuticals was trading at Rs 3,394.10 on the NSE as of 15 October 2026, and its 52-week range runs from Rs 1,561.00 to Rs 3,949.00. That leaves the share price 14 percent short of the 52-week high and 2.2 times the 52-week low. Its market capitalisation is Rs 3,520 Cr and its EPS (TTM) is Rs 78.11, which is the earnings figure behind the 43.43x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Kwality Pharmaceuticals belong to?

Ans. Kwality Pharmaceuticals is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.77x Industry P/E used in this article. The 2 named peers compared here are Ajanta Pharma and Marksans Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Kwality Pharmaceuticals compare to its sector peers on P/E?

Ans. Kwality Pharmaceuticals' P/E of 43.43x is above the 31.82x average of the 2 named peers, with Ajanta Pharma at 36.31x and Marksans Pharma at 27.32x. It also sits above the 36.77x Industry P/E, which is the benchmark for the wider Pharmaceuticals sector. A P/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 10.64 gives one more view of how the market values its book value.

What is Kwality Pharmaceuticals' return on equity?

Ans. Kwality Pharmaceuticals reported a return on equity of 20.31%, which is above the 18.57% average of its named peers, with Ajanta Pharma at 23.33% and Marksans Pharma at 13.82%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.39 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Kwality Pharmaceuticals based on its sector position?

Ans. Sector position is only one input into an investment decision. Kwality Pharmaceuticals has a 20.31% ROE and a 43.43x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.